Creative Planning Lowers Stock Holdings in GSK plc (NYSE:GSK)

Creative Planning trimmed its position in shares of GSK plc (NYSE:GSKGet Rating) by 18.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 155,919 shares of the pharmaceutical company’s stock after selling 35,439 shares during the quarter. Creative Planning’s holdings in GSK were worth $4,589,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Castle Wealth Management LLC purchased a new position in GSK during the 2nd quarter valued at about $28,000. CX Institutional purchased a new position in GSK during the 2nd quarter valued at about $32,000. Pflug Koory LLC purchased a new position in GSK during the 3rd quarter valued at about $26,000. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its holdings in GSK by 61.3% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock valued at $42,000 after acquiring an additional 368 shares during the period. Finally, Householder Group Estate & Retirement Specialist LLC purchased a new position in GSK during the 3rd quarter valued at about $31,000. 13.15% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Down 1.9 %

Shares of NYSE:GSK opened at $34.70 on Wednesday. The company has a quick ratio of 0.74, a current ratio of 0.97 and a debt-to-equity ratio of 2.22. GSK plc has a 52-week low of $28.47 and a 52-week high of $46.97. The stock’s fifty day simple moving average is $34.97 and its 200-day simple moving average is $34.54. The company has a market capitalization of $71.03 billion, a P/E ratio of 4.25, a P/E/G ratio of 1.19 and a beta of 0.66.

GSK (NYSE:GSKGet Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.19. GSK had a return on equity of 32.18% and a net margin of 37.88%. The business had revenue of $9.22 billion for the quarter, compared to the consensus estimate of $7.75 billion. As a group, equities research analysts forecast that GSK plc will post 3.3 earnings per share for the current fiscal year.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 12th. Stockholders of record on Friday, November 18th were given a $0.3695 dividend. The ex-dividend date was Thursday, November 17th. This represents a $1.48 annualized dividend and a dividend yield of 4.26%. GSK’s dividend payout ratio is currently 16.05%.

Analyst Ratings Changes

Several brokerages have recently issued reports on GSK. Bank of America cut GSK from a “neutral” rating to an “underperform” rating in a research note on Monday, December 5th. UBS Group lowered GSK from a “neutral” rating to a “sell” rating in a research report on Friday, November 11th. TheStreet raised GSK from a “c+” rating to a “b-” rating in a research report on Friday, December 30th. JPMorgan Chase & Co. lowered GSK from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 3rd. Finally, Citigroup dropped their price objective on GSK from GBX 1,975 ($24.45) to GBX 1,550 ($19.19) in a report on Friday, December 2nd. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $1,583.57.

GSK Company Profile

(Get Rating)

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.

Read More

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKGet Rating).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.